Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CXCR4R334X-engineered NK cells
- Development stage
- Preclinical
- Lead developer
- Karolinska Institutet
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
CXCR4R334X-engineered NK cells are an experimental, preclinical cell therapy consisting of ex vivo expanded human natural killer (NK) cells genetically engineered via mRNA transfection to transiently express the gain-of-function CXCR4 R334X variant (associated with WHIM syndrome). This modification is designed to enhance the homing capacity of the adoptively transferred NK cells to the bone marrow by targeting the CXCR4/SDF-1alpha (CXCL12) chemokine axis. Developed by researchers at the Karolinska Institutet and the National Institutes of Health (NIH), this therapy is being investigated for the treatment of bone-marrow-residing hematological malignancies, such as acute myeloid leukemia (AML) and multiple myeloma.
- Other names
- CXCR4R334X-expressing NK cellsCXCR-4R334X-expressing NK cellsCXCR 4R334X-expressing NK cellsCXCR4R334X-modified NK cellsCXCR-4R334X-modified NK cellsCXCR 4R334X-modified NK cells
Beyond the preview
Go deeper on CXCR4R334X-engineered NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CXCR4R334X-engineered NK cells.